| 摘要 |
The present invention relates to the use of IgG1 immunoglobulins, and more generally of ligands of the CD32 receptor, for treating inflammatory diseases and incidents, in particular allergies and autoimmune diseases, and more particularly for treating allergic asthma, wherein the immunoglobulins and the ligands are administered via a mucosal route, in particular via a sublingual route. |
| 申请人 |
STALLERGENES S.A.;BATARD, THIERRY;MOINGEON, PHILIPPE;MASCARELL, LAURENT;ZIMMER, ALINE;NONY, EMMANUEL |
发明人 |
BATARD, THIERRY;MOINGEON, PHILIPPE;MASCARELL, LAURENT;ZIMMER, ALINE;NONY, EMMANUEL |
